[1]
|
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版) [J]. 中华糖尿病杂志, 2021, 13(4): 315-409.
https://doi.org/10.3760/cma.j.cn115791-20210221-00095
|
[2]
|
Wander, P.L., Boyko, E.J., Leonetti, D.L., et al. (2013) Change in Visceral Adiposity Independently Predicts a Greater Risk of Developing Type 2 Diabetes over 10 Years in Japanese Americans. Diabetes Care, 36, 289-293.
https://doi.org/10.2337/dc12-0198
|
[3]
|
Amato, M.C., Giordano, C., Galia, M., et al. (2010) Visceral Adiposity In-dex: A Reliable Indicator of Visceral Fat Function Associated with Cardiometabolic Risk. Diabetes Care, 33, 920-922. https://doi.org/10.2337/dc09-1825
|
[4]
|
Chertow, G.M., Vart, P., Jongs, N., et al. (2021) Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. Journal of the American Society of Nephrology, 32, 2352-2361. https://doi.org/10.1681/ASN.2021020167
|
[5]
|
Dhillon, S. (2019) Dapagliflozin: A Review in Type 2 Diabetes. Drugs, 79, 1135-1146.
https://doi.org/10.1007/s40265-019-01148-3
|
[6]
|
Calapkulu, M., Cander, S., Gul, O.O., et al. (2019) Lipid Profile in Type 2 Diabetic Patients with New Dapagliflozin Treatment; Actual Clinical Experience Data of Six Months Retro-spective Lipid Profile from Single Center. Diabetes & Metabolic Syndrome, 13, 1031-1034. https://doi.org/10.1016/j.dsx.2019.01.016
|
[7]
|
Phrueksotsai, S., Pinyopornpanish, K., Euathrongchit, J., et al. (2021) The Effects of Dapagliflozin on Hepatic and Visceral Fat in Type 2 Diabetes Patients with Non-Alcoholic Fatty Liver Disease. Journal of Gastroenterology and Hepatology, 36, 2952-2959. https://doi.org/10.1111/jgh.15580
|
[8]
|
Plosker, G.L. (2012) Dapagliflozin: A Review of Its Use in Type 2 Diabetes Mellitus. Drugs, 72, 2289-2312.
https://doi.org/10.2165/11209910-000000000-00000
|
[9]
|
Merovci, A., Solis-Herrera, C., Daniele, G., et al. (2014) Dapagliflozin Improves Muscle Insulin Sensitivity but Enhances Endogenous Glucose Production. Journal of Clinical Investigation, 124, 509-514.
https://doi.org/10.1172/JCI70704
|
[10]
|
González, N., Moreno-Villegas, Z., González-Bris, A., et al. (2017) Regula-tion of Visceral and Epicardial Adipose Tissue for Preventing Cardiovascular Injuries Associated to Obesity and Diabetes. Cardiovascular Diabetology, 16, 44.
https://doi.org/10.1186/s12933-017-0528-4
|
[11]
|
Randrianarisoa, E., Lehn-Stefan, A., Hieronimus, A., et al. (2019) Visceral Adiposity Index as an Independent Marker of Subclinical Atherosclerosis in Individuals Prone to Diabetes Mellitus. Journal of Atherosclerosis and Thrombosis, 26, 821-834. https://doi.org/10.5551/jat.47274
|
[12]
|
Yamazaki, H., Tauchi, S., Machann, J., et al. (2022) Fat Distribution Patterns and Future Type 2 Diabetes. Diabetes, 71, 1937-1945. https://doi.org/10.2337/db22-0315
|
[13]
|
Baloglu, I., Turk-men, K., Selcuk, N.Y., et al. (2021) The Relationship between Visceral Adiposity Index and Epicardial Adipose Tissue in Patients with Type 2 Diabetes Mellitus. Experimental and Clinical Endocrinology & Diabetes, 129, 390-395. https://doi.org/10.1055/a-0892-4290
|
[14]
|
Wiviott, S.D., Raz, I., Bonaca, M.P., et al. (2019) Dapagliflozin and Car-diovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine, 380, 347-357. https://doi.org/10.1056/NEJMoa1812389
|
[15]
|
Heerspink, H.J.L., Stefánsson, B.V., Correa-Rotter, R., et al. (2020) Dapagliflozin in Patients with Chronic Kidney Disease. The New England Journal of Medicine, 383, 1436-1446. https://doi.org/10.1056/NEJMoa2024816
|
[16]
|
Mcgurnaghan, S.J., Brierley, L., Caparrotta, T.M., et al. (2019) The Effect of Dapagliflozin on Glycaemic Control and Other Cardiovascular Disease Risk Factors in Type 2 Diabetes Melli-tus: A Real-World Observational Study. Diabetologia, 62, 621-632. https://doi.org/10.1007/s00125-018-4806-9
|
[17]
|
Viswanathan, V., Singh, K.P. (2019) Use of Dapagliflozin in the Management of Type 2 Diabetes Mellitus: A Real-World Evidence Study in Indian Patients (FOREFRONT). Diabetes Technology & Therapeutics, 21, 415-422.
https://doi.org/10.1089/dia.2019.0052
|
[18]
|
Basu, D., Huggins, L.A., Scerbo, D., et al. (2018) Mechanism of In-creased LDL (Low-Density Lipoprotein) and Decreased Triglycerides with SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition. Arteriosclerosis, Thrombosis, and Vascular Biology, 38, 2207-2216. https://doi.org/10.1161/ATVBAHA.118.311339
|
[19]
|
Fadini, G.P., Bonora, B.M., Zatti, G., et al. (2017) Effects of the SGLT2 Inhibitor Dapagliflozin on HDL Cholesterol, Particle Size, and Cholesterol Efflux Capacity in Patients with Type 2 Diabetes: A Randomized Placebo-Controlled Trial. Cardiovascular Diabetology, 16, 42. https://doi.org/10.1186/s12933-017-0529-3
|
[20]
|
Koshizaka, M., Ishikawa, K., Ishibashi, R., et al. (2019) Compar-ing the Effects of Ipragliflozin versus Metformin on Visceral Fat Reduction and Metabolic Dysfunction in Japanese Pa-tients with Type 2 Diabetes Treated with Sitagliptin: A Prospective, Multicentre, Open-Label, Blinded-Endpoint, Ran-domized Controlled Study (PRIME-V Study). Diabetes, Obesity and Metabolism, 21, 1990-1995. https://doi.org/10.1111/dom.13750
|
[21]
|
Yaribeygi, H., Maleki, M., Reiner, Ž., et al. (2022) Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu. Journal of Clinical Medicine, 11, 6544. https://doi.org/10.3390/jcm11216544
|
[22]
|
Sasaki, T., Sugawara, M. and Fukuda, M. (2019) Sodium-Glucose Co-transporter 2 Inhibitor-Induced Changes in Body Composition and Simultaneous Changes in Metabolic Profile: 52-Week Prospective LIGHT (Luseogliflozin: The Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study. Journal of Diabetes Investigation, 10, 108-117. https://doi.org/10.1111/jdi.12851
|
[23]
|
Alkhalaqi, A., Al-Naimi, F., Qassmi, R., et al. (2020) Visceral Adiposity Index Is a Better Predictor of Type 2 Diabetes than Body Mass Index in Qatari Population. Medicine (Baltimore), 99, e21327.
https://doi.org/10.1097/MD.0000000000021327
|
[24]
|
Wu, Z., Yu, S., Kang, X., et al. (2022) Association of Vis-ceral Adiposity Index with Incident Nephropathy and Retinopathy: A Cohort Study in the Diabetic Population. Cardio-vascular Diabetology, 21, 32.
https://doi.org/10.1186/s12933-022-01464-1
|
[25]
|
Jiang, K., Luan, H., Pu, X., et al. (2022) Association between Visceral Adiposity Index and Insulin Resistance: A Cross-Sectional Study Based on US Adults. Frontiers in Endocri-nology (Lausanne), 13, Article ID: 921067.
https://doi.org/10.3389/fendo.2022.921067
|
[26]
|
Taylor, R., Al-Mrabeh, A., Zhyzhneuskaya, S., et al. (2018) Re-mission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capac-ity for β Cell Recovery. Cell Metabolism, 28, 547-556.e3. https://doi.org/10.1016/j.cmet.2018.07.003
|